Medtrum and the TouchCare Nano System
Medtrum’s nano-technology and smartphone-based solutions have entered countries including the UK, Germany, Italy, the Netherlands, Denmark, France, Spain and Sweden. With 18 years of sustained focus and persistence, Medtrum has rapidly grown into an innovation leader in the diabetes devices industry, delivering a series of pioneering technologies. These include a compact and ultra-thin tubeless patch pump (the Nano Pump) fully controlled by a smartphone app, a real-time 14-day CGM (Nano CGM), and a tubeless automated insulin delivery (AID) system based on Medtrum’s proprietary APGO® algorithm.
Scott Yang founded Medtrum with the vision of leveraging semiconductor and information technologies to help millions of people with diabetes enjoy a better life. As a chronic disease, Type 1 diabetes currently cannot be cured and can only be managed. Reflecting on his motivation, Yang says:“I was inspired to found Medtrum when I saw how people with diabetes persevere in the face of daily challenges. Diabetes places a significant burden on people’s lives. Through continuous exploration and innovation, we hope to make life easier and simpler for people with diabetes. This is our commitment to the global diabetes community.”
Yang believes that patients deserve better devices and a better user experience, enabled by technological advances and innovation. He strongly believes that AID systems represent a highly promising future solution for insulin-dependent people, and that tubeless patch pumps and CGM systems designed to operate without routine calibration are key directions for the future.
From the moment Medtrum was founded in 2008, the company adopted a clear strategy to develop three technologies in parallel: a tubeless patch pump, a CGM system, and an AID system. Medtrum is one of the very few companies globally that has pursued the simultaneous development of all three technologies from its inception.
Transitioning from the semiconductor industry to the medical device industry presented Yang with a unique set of challenges. In his view, diabetes medical devices represent a convergence of electronics, semiconductors, software, mechanics, algorithms, chemistry and functional materials—extending well beyond the scope of traditional medical technology. He believes that only a truly multidisciplinary team can challenge conventional thinking, develop disruptive technologies, reshape business models and deliver meaningful innovation.
A Full Range of Products
Yang believes that prior experience and established track records in diabetes devices can sometimes become barriers to innovation. As a result, Medtrum’s founding team brings together talent from a wide range of industries. The company has consistently adhered to a strategy of high vertical integration, maintaining direct ownership of key stages across the product lifecycle and full control of core technologies.
The tubeless patch pump, CGM system and closed-loop algorithms are all developed in-house. Following years of sustained investment in research and development, Medtrum has become the only company in the diabetes sector able to offer a complete portfolio across these technologies, with devices widely regarded as smaller, lighter and smarter than many competing solutions.
Uniquely, the Nano pump and Nano CGM are designed to operate as standalone devices. When seamlessly integrated, however, they enable additional safety features such as a Predictive Low Glucose Suspend function, helping to reduce the risk of hypoglycaemia. Both the Nano tubeless insulin pump and Nano CGM can be controlled remotely using a compatible smartphone, with the Medtrum EasyPatch App providing users with greater convenience and freedom compared with traditional systems.
All pump and CGM data can be easily shared with an unlimited number of family members or carers via the Medtrum EasyFollow app, or with healthcare professionals for remote support using Medtrum EasyView reports.
The TouchCare Nano System has officially launched its Automated Insulin Delivery (AID) functionality and is now being used in real-world clinical settings. Powered by Medtrum’s proprietary APGO® algorithm, the AID system works seamlessly with the Nano pump and CGM to automatically adjust insulin delivery, helping users achieve more consistent glucose control.
